AI Biomed PredictionsNGEN – NervGen’s next rerating likely hinges on 2Q clinical follow-through ScanScor Admin / May 10, 2026
AI Biomed PredictionsLRMR – June BLA filing could reset Larimar’s risk-reward profile ScanScor Admin / May 10, 2026
AI Biomed PredictionsAUTL – Autolus Faces Its First True Commercial Rerating Test ScanScor Admin / May 10, 2026
AI Biomed PredictionsABEO – ZEVASKYN launch proof could ignite Abeona’s next sharp rerating ScanScor Admin / May 10, 2026
AI Biomed PredictionsNMRA – Phase 3 Redemption Window Nears for Beaten-Down Neumora Shares ScanScor Admin / May 10, 2026
AI Biomed PredictionsTNYA – ASGCT TN-401 data could decide Tenaya’s next sharp rerating ScanScor Admin / May 2, 2026
AI Biomed PredictionsPYPD – PolyPid Nears NDA Completion With Regulatory Repricing Potential ScanScor Admin / May 2, 2026
AI Biomed PredictionsPRQR – AX-0810 Human Proof-of-Mechanism Could Reprice ProQR Quickly ScanScor Admin / May 2, 2026
AI Biomed PredictionsOSTX – OSTX Faces Its Defining FDA Pathway Test This Month ScanScor Admin / May 2, 2026
AI Biomed PredictionsINO – Depressed Inovio May Rebound on FDA Review Reassurance ScanScor Admin / May 2, 2026
